Under 10% of individuals eligible to benefit from GLP-1 drugs like Wegovy can access them, states the WHO as it publishes its initial guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is urging increased and just access to this class of drugs.
According to forecasts, more than two billion will be obese by 2030 unless action is taken.
"Our new guidance affirms that excess weight is a lifelong illness that can be managed with holistic and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key hurdles to broad access to the treatments that can assist patients in reducing considerable weight, explains the body.
Skinny Jab Shortage
Even under the current best projected case, the production of these medications would only suffice for about 100 million people – under 10% of the global need, per the health organization.
The advice encourages governments and firms to increase availability, by approaches like licensing agreements.
Exclusive production rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
How Obesity Injections Operate
GLP-1 drugs replicate a natural hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so users eat less.
Individuals usually start to lose weight after several weeks of commencing the regular doses.
Studies indicates patients may regain a significant portion a year later of stopping the medication, when their normal food cravings resume.
To be carrying excess weight raises your likelihood for experiencing medical conditions, such as type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns people in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
